SEAVUE: Ustekinumab vs Adalimumab for Crohn ' s Disease SEAVUE: Ustekinumab vs Adalimumab for Crohn ' s Disease

For biologic-naive adults with moderate to severe Crohn ' s disease, treatment with either adalimumab or ustekinumab leads to similar outcomes, according to results of the head-to-head SEAVUE trial.Medscape Medical News
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Gastroenterology News Source Type: news